What is NDC 71335-3152?

71335-3152 is the product NDC for Buprenorphine, Buprenorphine hydrochloride 8 mg/1 tablet, listed with the FDA by Bryant Ranch Prepack. It has 10 package NDCs, shown above in 10- and 11-digit form.

Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Buprenorphine?

53 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Buprenorphine NDC 71335-3152 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)71335-3152Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71335-3152Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
71335-3152-0	7133531520071335315200	120 TABLET in 1 BOTTLE (71335-3152-0)Marketed from Jun 29, 2026
71335-3152-1	7133531520171335315201	90 TABLET in 1 BOTTLE (71335-3152-1)Marketed from Jun 29, 2026
71335-3152-2	7133531520271335315202	60 TABLET in 1 BOTTLE (71335-3152-2)Marketed from Jun 29, 2026
71335-3152-3	7133531520371335315203	30 TABLET in 1 BOTTLE (71335-3152-3)Marketed from Jun 29, 2026
71335-3152-4	7133531520471335315204	20 TABLET in 1 BOTTLE (71335-3152-4)Marketed from Jun 29, 2026
71335-3152-5	7133531520571335315205	7 TABLET in 1 BOTTLE (71335-3152-5)Marketed from Jun 29, 2026
71335-3152-6	7133531520671335315206	28 TABLET in 1 BOTTLE (71335-3152-6)Marketed from Jun 29, 2026
71335-3152-7	7133531520771335315207	1 TABLET in 1 BOTTLE (71335-3152-7)Marketed from Jun 29, 2026
71335-3152-8	7133531520871335315208	12 TABLET in 1 BOTTLE (71335-3152-8)Marketed from Jun 29, 2026
71335-3152-9	7133531520971335315209	14 TABLET in 1 BOTTLE (71335-3152-9)Marketed from Jun 29, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Buprenorphine
Generic name (nonproprietary): buprenorphine
Active ingredients: Buprenorphine hydrochloride — 8 mg/1
Dosage form: Tablet
Route: Sublingual
Labeler: Bryant Ranch PrepackNDC labeler code 71335
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201760
Marketing start: Feb 17, 2016
Listing expires: Dec 31, 2027
DEA schedule: CIII
Other FDA classes: Partial Opioid Agonists (Mechanism)
Identifiers: Product ID 71335-3152_d92fb8ed-3604-4836-8415-482b46a684f0SPL ID d92fb8ed-3604-4836-8415-482b46a684f0SPL set ID 655e3e52-03be-496c-978a-5cffc74b2ae4RxCUI 351265UNII 56W8MW3EN1
Pharmacologic class: Partial Opioid Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Sublingual products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335315200 followed by a unit qualifier and the quantity

Package 71335-3152-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 29, 2026.

Indications (excerpt from the label)

Buprenorphine sublingual tablet is indicated for the treatment of opioid dependence and is preferred for induction. Buprenorphine sublingual tablet should be used as part of a complete treatment plan to include counseling and psychosocial support. Buprenorphine sublingual tablet, contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of opioid dependence and is preferred for induction. (1) Buprenorphine sublingual tablet should be used as part of a complete treatment plan that includes counseling and psychosocial support. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 71335-3152

What is NDC 71335-3152?: 71335-3152 is the product NDC for Buprenorphine, Buprenorphine hydrochloride 8 mg/1 tablet, listed with the FDA by Bryant Ranch Prepack. It has 10 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Buprenorphine.
What is the active ingredient?: Buprenorphine hydrochloride.
Who is the labeler?: Bryant Ranch Prepack, NDC labeler code 71335. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Buprenorphine?: 53 other product NDCs are listed under this name. See all Buprenorphine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Buprenorphine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	Unit Dose Solutions, Inc.	87441-082	87441-0082-01
Buprenorphine	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	Unit Dose Solutions, Inc.	87441-011	87441-0011-01
Buprenorphine	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	AvPAK	50268-128	50268-0128-15
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	AvPAK	50268-129	50268-0129-15
Buprenorphine	Buprenorphine 5 ug/h	Patch, Extended releaseTransdermal	Aveva Drug Delivery Systems Inc.	3215-1521	03215-1521-04
Buprenorphine	Buprenorphine 7.5 ug/h	Patch, Extended releaseTransdermal	Aveva Drug Delivery Systems Inc.	3215-1522	03215-1522-04
Buprenorphine	Buprenorphine 10 ug/h	Patch, Extended releaseTransdermal	Aveva Drug Delivery Systems Inc.	3215-1523	03215-1523-04
Buprenorphine	Buprenorphine 15 ug/h	Patch, Extended releaseTransdermal	Aveva Drug Delivery Systems Inc.	3215-1524	03215-1524-04
Buprenorphine	Buprenorphine 20 ug/h	Patch, Extended releaseTransdermal	Aveva Drug Delivery Systems Inc.	3215-1525	03215-1525-04
Buprenorphine	Buprenorphine 5 ug/h	Patch, Extended releaseTransdermal	INGENUS PHARMACEUTICALS, LLC	50742-372	50742-0372-04

All 54 Buprenorphine NDCs

Other NDCs under ANDA 201760

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 201760
Product	Strength	Form · route	Labeler	Product NDC
Buprenorphine	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	AvPAK	50268-128
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	AvPAK	50268-129
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	Clinical Solutions Wholesale, LLC	58118-0460
Buprenorphine	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	Clinical Solutions Wholesale, LLC	58118-4459
Buprenorphine	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	Sun Pharmaceutical Industries, Inc.	62756-459
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	Sun Pharmaceutical Industries, Inc.	62756-460
Buprenorphine	Buprenorphine hydrochloride 8 mg/1	TabletSublingual	Redpharm Drug	67296-2173
Buprenorphine Sublingual	Buprenorphine hydrochloride 2 mg/1	TabletSublingual	Direct_rx	72189-579